Drugs / LUMISTOBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05351697 | Apr 2022 → Oct 2025 | cancer | BioRay Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUMISTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068135 ↗ |
| Known as | BR105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05351697 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068135 ↗ |
| Route | Intravenous | “intravenous infusion of BR105” NCT05351697 ↗ |